s6y

Allarity Therapeutics, Inc.

Ticker
ALLR
CIK
1860657
Industry
Pharmaceutical Preparations

Financials 27

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. 10-K Annual Report for period ending Dec 31, 2024
  10. 10-Q Quarterly Report for period ending Sep 30, 2024

All 27 financials filings

News 162

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 162 news filings

Ownership 51

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4/A Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 3 Initial statement of beneficial ownership of securities

All 51 ownership filings

Prospectus 87

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. S-3/A Registration statement for specified transactions by certain issuers
  4. S-3 Registration statement for specified transactions by certain issuers
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. S-3 Registration statement for specified transactions by certain issuers
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. S-3 Registration statement for specified transactions by certain issuers
  9. RW Registration Withdrawal Request
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

All 87 prospectus filings

Proxies 26

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEF 14A Definitive proxy statements
  6. DEFR14A Definitive revised proxy soliciting materials
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  10. DEF 14A Definitive proxy statements

All 26 proxies filings

Other 53

  1. ARS Annual report to security holders
  2. EFFECT Notice of Effectiveness
  3. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  4. UPLOAD Letter (PDF)
  5. EFFECT Notice of Effectiveness
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. EFFECT Notice of Effectiveness
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. UPLOAD Letter (PDF)

All 53 other filings